文献速递重症综合管理与镇静镇痛

异基因造血干细胞移植受者重症监护结局

Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论法国14个ICU多中心回顾性队列显示,重症异基因造血干细胞移植受者90天生存率达51.8%,2个及以上死亡危险因素者需仔细评估治疗目标。

该多中心回顾性队列纳入2015年1月1日至2020年12月31日法国14个ICU收治的1164例异基因造血干细胞移植患者,主要终点为90天死亡率。入ICU时66%(765例)存在多器官功能障碍,40%(461例)为急性呼吸衰竭,SOFA评分中位数6分(IQR 4-8);38%(438例)需有创机械通气,19%(221例)需肾脏替代治疗,41%(468例)需血管活性药物。ICU死亡率26%(302例死亡),90天、1年、3年死亡率分别为48%、63%、70%。多因素分析显示年龄>56岁、移植至入ICU时间30-90天、激素难治性急性移植物抗宿主病、需血管活性药物、需机械通气与90天死亡率独立相关。作者认为多数重症患者存活出院,但2个及以上死亡危险因素者需仔细评估治疗目标。

要点

  • 1164例异基因造血干细胞移植ICU患者中,ICU死亡率26%(302例死亡),90天死亡率48%,总体90天生存率51.8%。
  • 入ICU时66%(765例)存在多器官功能障碍,40%(461例)为急性呼吸衰竭,SOFA评分中位数6分(IQR 4-8)。
  • 38%(438例)需有创机械通气,19%(221例)需肾脏替代治疗,41%(468例)需血管活性药物。
  • 90天死亡独立危险因素:年龄>56岁(OR 2.0,95%CI 1.53-2.60,P<0.001)、移植至入ICU 30-90天(OR 1.68,95%CI 1.17-2.40,P=0.005)、激素难治性急性GVHD(OR 1.63,95%CI 1.38-1.93,P<0.001)、需血管活性药物(OR 1.9,95%CI 1.42-2.55,P<0.001)、机械通气(OR 3.1,95%C
  • 需机械通气者中,无其他死亡危险因素者死亡率39%,有4个相关死亡危险因素者死亡率达100%。

适用人群与场景

  • 2015年1月1日至2020年12月31日入住法国14个ICU的异基因造血干细胞移植患者,共1164例。

研究设计与关键结果

  • 多中心回顾性队列,纳入法国14个ICU的1164例异基因造血干细胞移植患者,主要终点为90天死亡率。
  • 入ICU时66%(765例)存在多器官功能障碍,急性呼吸衰竭占40%(n=461),SOFA评分中位数6分(IQR 4-8)。
  • 38%(438例)需有创机械通气,19%(221例)需肾脏替代治疗,41%(468例)需血管活性药物。
  • ICU死亡率26%(302例死亡);90天、1年、3年死亡率分别为48%、63%、70%。
  • 多因素分析:年龄>56岁OR 2.0(95%CI 1.53-2.60,P<0.001);移植至入ICU 30-90天OR 1.68(95%CI 1.17-2.40,P=0.005);激素难治性急性GVHD OR 1.63(95%CI 1.38-1.93,P<0.001);需血管活性药物OR 1.9(95%CI 1.42-2.55,P<0.001);机械通气OR 3.1(95%CI 2.29-4.18,P<0.001),均与90天死亡率独立相关。
  • 需机械通气患者中,无其他死亡危险因素者死亡率39%,有4个相关死亡危险因素者死亡率100%。
  • 总体90天生存率为51.8%。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,多数重症异基因造血干细胞移植受者(包括需机械通气者)能存活过ICU阶段,总体90天生存率达51.8%。
  • 作者认为,对存在2个及以上死亡危险因素的患者,需仔细评估治疗目标。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients are still believed to be poor candidates for ICU management. Methods: We investigated outcomes and determinants of mortality in a large multicenter retrospective cohort of Allo-HSCT patients admitted between January 1, 2015, and December 31, 2020, to 14 French ICUs. The primary endpoint was 90-day mortality. Measurements and Main Results: In total, 1,164 patients were admitted throughout the study period. At the time of ICU admission, 765 (66%) patients presented with multiple organ dysfunction, including acute respiratory failure in 40% (n = 461). The median sepsis-related organ failure assessment score was 6 (interquartile range, 4-8). Invasive mechanical ventilation, renal replacement therapy, and vasopressors were required in 438 (38%), 221 (19%), and 468 (41%) patients, respectively. ICU mortality was 26% (302 deaths). Ninety-day, 1-year, and 3-year mortality rates were 48%, 63%, and 70%, respectively. By multivariable analysis, age > 56 years (odds ratio [OR], 2.0 [95% confidence interval (CI), 1.53-2.60]; P < 0.001), time from Allo-HSCT to ICU admission between 30 and 90 days (OR, 1.68 [95% CI, 1.17-2.40]; P = 0.005), corticosteroid-refractory acute graft-versus-host disease (OR, 1.63 [95% CI, 1.38-1.93]; P < 0.001), need for vasopressors (OR, 1.9 [95% CI, 1.42-2.55]; P < 0.001), and mechanical ventilation (OR, 3.1 [95% CI, 2.29-4.18]; P < 0.001) were independently associated with 90-day mortality. In patients requiring mechanical ventilation, mortality rates ranged from 39% (no other risk factors for mortality) to 100% (four associated risk factors for mortality). Conclusions: Most critically ill Allo-HSCT recipients survive their ICU stays, including those requiring mechanical ventilation, with an overall 90-day survival rate reaching 51.8%. A careful assessment of goals of care is required in patients with two or more risk factors for mortality.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lafarge A, Dupont T, Canet E, et al. Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients. Am J Respir Crit Care Med. 2024. PMID: 39018219. doi:10.1164/rccm.202401-0135OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。